Tagrisso Tablets Clinical Experience Investigation (All case investigation)

Trial Identifier: D5160C00025
Sponsor: AstraZeneca
NCTID:: NCT02756039
Start Date: May 2016
Primary Completion Date: August 2018
Study Completion Date: August 2018
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Aichi, Japan, D5160C00025
Japan Akita, Japan, D5160C00025
Japan Aomori, Japan, D5160C00025
Japan Chiba, Japan, D5160C00025
Japan Ehime, Japan, D5160C00025
Japan Fukui, Japan, D5160C00025
Japan Fukuoka, Japan, D5160C00025
Japan Fukushima, Japan, D5160C00025
Japan Gifu, Japan, D5160C00025
Japan Gunma, Japan, D5160C00025
Japan Hiroshima, Japan, D5160C00025
Japan Hokkaido, Japan, D5160C00025
Japan Hyogo, Japan, D5160C00025
Japan Ibaraki, Japan, D5160C00025
Japan Ishikawa, Japan, D5160C00025
Japan Iwate, Japan, D5160C00025
Japan Kagawa, Japan, D5160C00025
Japan Kagoshima, Japan, D5160C00025
Japan Kanagawa, Japan, D5160C00025
Japan Kochi, Japan, D5160C00025
Japan Kumamoto, Japan, D5160C00025
Japan Kyoto, Japan, D5160C00025
Japan Mie, Japan, D5160C00025
Japan Miyagi, Japan, D5160C00025
Japan Miyazaki, Japan, D5160C00025
Japan Nagano, Japan, D5160C00025
Japan Nagasaki, Japan, D5160C00025
Japan Nara, Japan, D5160C00025
Japan Niigata, Japan, D5160C00025
Japan Oita, Japan, D5160C00025
Japan Okayama, Japan, D5160C00025
Japan Okinawa, Japan, D5160C00025
Japan Osaka, Japan, D5160C00025
Japan Saga, Japan, D5160C00025
Japan Saitama, Japan, D5160C00025
Japan Shiga, Japan, D5160C00025
Japan Shimane, Japan, D5160C00025
Japan Shizuoka, Japan, D5160C00025
Japan Tochigi, Japan, D5160C00025
Japan Tokushima, Japan, D5160C00025
Japan Tokyo, Japan, D5160C00025
Japan Tottori, Japan, D5160C00025
Japan Toyama, Japan, D5160C00025
Japan Wakayama, Japan, D5160C00025
Japan Yamagata, Japan, D5160C00025
Japan Yamaguchi, Japan, D5160C00025
Japan Yamanashi, Japan, D5160C00025